</>Build with Tariff Intelligence|Programmatic access to tariff calculations and HS code classification.Explore Developer Resources →

Mixed Monoclonal Antibody Cocktail for Cancer Immunotherapy

This product is a blend of multiple monoclonal antibodies (e.g., pembrolizumab and nivolumab derivatives) designed for immunotherapy treatment of solid tumors. It falls under HTS 3002.14.00.90 as mixed immunological products not in measured doses or retail packaging, per chapter notes defining immunological products as peptides/proteins regulating immunological processes.

Import Duty Rates by Country of Origin

Origin CountryMFN RateCh.99 SurchargesTotal Effective Rate
🇨🇳ChinaFreeFree
🇲🇽MexicoFreeFree
🇨🇦CanadaFreeFree
🇩🇪GermanyFreeFree
🇯🇵JapanFreeFree

Alternative Classifications

This product could be classified differently depending on its characteristics or intended use.

3002.13.00Same rate: Free

If not mixed, supplied as individual monoclonal antibodies

Unmixed immunological products like single MABs classify under 3002.13, while mixtures move to 3002.14 per chapter note 3(a).

3002.90.10.00Same rate: Free

If put up in measured doses for retail sale

Retail-packed versions shift to 3002.90 as they no longer qualify as 'not put up in measured doses' under 3002.14.

2937.19.00.00Same rate: Free

If classified primarily as hormones rather than immunological regulators

Certain biotech products based on heading 2937 hormones exclude from chapter 30 immunological definitions.

Not sure which classification is right?

Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.

Import Tips & Compliance

Obtain FDA biologics license application (BLA) approval prior to import; provide lot-specific certificates of analysis

Declare as mixed immunological product; avoid retail packaging to stay in 3002.14, include biotech process details